85X0 Stock Chart & Stats
€0.17
-€0.03(-9.58%)
At close: 4:00 PM EST
€0.17
-€0.03(-9.58%)
Day’s Range― - ―
52-Week Range€0.15 - €0.34
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.91M
Enterprise Value€109.23
Total Cash (Recent Filing)€7.39M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding47,601,730
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.23
Price to Sales (P/S)146.53
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€157.76K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet reduces refinancing exposure and interest costs, preserving financial flexibility while the company develops its technology and commercial opportunities. This structure can help management direct available resources toward operations and growth rather than servicing lenders.
Fermentation-based Ingredient PlatformBioextrax’s fermentation-based platform addresses several end markets, including food, cosmetics, and broader industrial applications. This market breadth gives the company multiple potential commercialization paths and could support longer-term revenue diversification if products gain customer adoption.
Evidence Of Operating Leverage PotentialThe positive gross profit achieved in 2023 indicates that the underlying model has previously shown some ability to generate contribution above direct costs. Re-establishing that performance could improve scalability and reduce the earnings burden as commercial volumes develop.
Bears Say
Small And Declining Revenue BaseA very small revenue base combined with declines in both 2024 and 2025 indicates that commercialization has not yet reached durable scale. Continued weak top-line performance limits operating leverage, constrains reinvestment capacity, and increases dependence on future customer traction.
Structurally Weak ProfitabilityPersistent gross, operating, and net losses show that the current cost base is far above the revenue scale the business has achieved. Unless margins and volume improve materially, ongoing losses can continue eroding equity and restrict the company’s ability to fund development internally.
Accelerating Cash BurnNegative operating and free cash flow across all reported years means the company is not self-funding its activities. The sharper burn in 2025 raises the likelihood of future external funding needs, which could constrain strategic flexibility and increase financing dependence.
85X0 FAQ
What was Bioextrax AB’s price range in the past 12 months?
Bioextrax AB lowest stock price was €0.15 and its highest was €0.34 in the past 12 months.
What is Bioextrax AB’s market cap?
Bioextrax AB’s market cap is €9.91M.
When is Bioextrax AB’s upcoming earnings report date?
Bioextrax AB’s upcoming earnings report date is Nov 20, 2026 which is in 65 days.
How were Bioextrax AB’s earnings last quarter?
Bioextrax AB released its earnings results on Aug 21, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.008 by >-€0.001.
Is Bioextrax AB overvalued?
According to Wall Street analysts Bioextrax AB’s price is currently Overvalued.
Does Bioextrax AB pay dividends?
Bioextrax AB does not currently pay dividends.
What is Bioextrax AB’s EPS estimate?
Bioextrax AB’s EPS estimate is >-0.01.
How many shares outstanding does Bioextrax AB have?
Bioextrax AB has 47,601,730 shares outstanding.
What happened to Bioextrax AB’s price movement after its last earnings report?
Bioextrax AB reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.008. Following the earnings report the stock price went up 0.562%.
Which hedge fund is a major shareholder of Bioextrax AB?
Currently, no hedge funds are holding shares in DE:85X0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioextrax AB
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.
Technical Analysis
Xintela AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―
Annexin Pharmaceuticals AB
―